Plain-English translation of NCT07131059 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing personalized medication combinations for people with acute myeloid leukemia (AML) who have responded well to initial treatment but still have minimal residual disease—meaning trace amounts of leukemia cells are detected by sensitive blood tests. The specific medications you receive depend on your leukemia's genetic mutations. The goal is to prevent the disease from coming back while monitoring how well the treatment works and how safe it is.
Even when people with AML achieve complete remission after initial treatment, tiny amounts of leukemia cells can remain and potentially cause relapse. This trial is testing whether personalized targeted medications—chosen based on your specific genetic mutations—can eliminate these remaining cells and improve long-term survival.
You likely qualify if…
You likely don't qualify if…
You will receive personalized medication based on your leukemia's specific genetic mutations. Your treatment regimen will be selected by your doctor and may include one or more of several targeted medications or chemotherapy drugs, given in cycles over multiple weeks. Throughout treatment, your doctors will monitor your response with blood tests and bone marrow checks. You can have a stem cell transplant at any point during the study if your doctor recommends it. The study will track how well the treatment works, how long you remain disease-free, and how safe the medication is for you.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China